000			03354cam a2200349 a 4500
003			EG-GiCUC
005			20250223032910.0
008			220109s2021 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aPh.D
099			_aCai01.08.05.Ph.D.2021.Kh.D
100	0		_aKholoud Fouad Aljamal
245	1	0	_aDesignand synthesis of novel pyridopyrimidine derivatives of anticipated anti-cancer activity / _cKholoud Fouad Aljamal ; Supervised Amal Abdelhaleem Eissa , Heba Abdelrasheed Allam , Hany Said Ibrahim
246	1	5	_aتصميم وتشييد مشتقات البيريدوبيريميدين الجديدة المتوقع لها فعالية كمضادات للسرطان
260			_aCairo : _bKholoud Fouad Aljamal , _c2021
300			_a145 P. : _bcharts ; _c25cm
502			_aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutical Chemistry
520			_aCancers are a large family of diseases that involve abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer is the second cause of mortality after cardiac diseases in the world. It is continuing to act as a major problem of health in both developing and developed countries. Accordingly, the search for new anticancer agents is extremely desirable to improve survival rates and minimize toxicities and drug resistance.Many researchers reported the importance of pyrido[2,3-d]pyrimidine as an interesting bioactive scaffold implicated in the development of anticancer agents. Also, literature survey highlighted the apoptotic activity of certain pyrido[2,3-d]pyrimidines leading to their anticancer effect. Accordingly, this research focused on the synthesis of novel pyrido[2,3-d]pyrimidines hoping to obtain promising anticancer agents with fewer side effects.The present investigation deals with the synthesis of bicyclic derivatives, namely: (4-substituted phenyl)pyrido[2,3-d] pyrimidin-4-amine IVa-h, 7-(4-methoxyphenyl)-4-(phenylamino)5-(4-substituted phenyl)pyrido[2,3-d] pyrimidin-2(1H)-thione Va-d, 1-(7-(4-methoxyphenyl)-3-phenyl-5-(4-substituted phenyl)-2-thioxo-2,3-dihydro pyrido[2,3-d]pyrimidin-4-yl)-3-phenyl thiourea VIa-d, 5-(4-(methylthio) phenyl)-7-(4-(un)substitute dphenyl)-2-thioxo-2,3-dihydropyrido[2,3-d] pyrimidin-4(1H)-one VIIa-d, 2-hydrazinyl-5-(4-(methylthio) phenyl)-7-(4-(un)substituted phenyl)pyrido [2,3-d]pyrimidin-4(3H)-one VIIIa,b, in addition to tricyclic derivatives: 3-amino-6-(4-(methylthio)phenyl)-8-(4-(un)substituted phenyl)-pyrido[2,3-d] [1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-one IXa,b ,6-(4-(methyl thio)phenyl)- vii 8-(4-(un)substituted phenyl)-3-thioxo-2,3-dihydropyrido[2,3-d][1,2,4] triazolo[4,3-a]pyrimidin-5(1H)-one Xa,b. Compounds IVa-h, Va-d, VIa-d, VIIa-d and VIIIa,b were evaluated for their anticancer activity as EGFR inhibitors, using Gefitinib as a reference compound
530			_aIssued also as CD
653		4	_aAnti-cancer activity
653		4	_aPyridopyrimidine
653		4	_aPyrimidines
700	0		_aAmal Abdelhaleem Eissa , _eSupervisor
700	0		_aHany Said Ibrahim , _eSupervisor
700	0		_aHeba Abdelrasheed Allam , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c83904 _d83904